Sign in
8-K

Current Report

Dianthus Therapeutics, Inc. /DE/ Filed Acc 0001193125-23-026931

Results of operations · Exit or restructuring costs · Executive or director change

  • Item 2.02 Results of operations and financial condition
  • Item 2.05 Costs associated with exit or disposal activities
  • Item 5.02 Departure or appointment of directors or officers

From the SEC's structured data for this filing